================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   ----------

                                    FORM 8-K
                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

        Date of report (Date of earliest event reported): August 25, 2006

                               Immunomedics, Inc.
               --------------------------------------------------
               (Exact Name of Registrant as Specified in Charter)

            Delaware                   000-12104               61-1009366
  ----------------------------        -----------          -------------------
  (State or Other Jurisdiction        (Commission             (IRS Employer
       of Incorporation)              File Number)         Identification No.)

     300 American Road, Morris Plains, New Jersey                 07950
     --------------------------------------------              ----------
       (Address of Principal Executive Offices)                (Zip Code)

                                 (973) 605-8200
                         (Registrant's telephone number,
                              including area code)

                                 Not applicable
          -------------------------------------------------------------
          (Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:

[ ]  Written communications pursuant to Rule 425 under the Securities
     Act (17 CFR 230.425).

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange
     Act (17 CFR 240.14a-12).

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b)).

[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c)).

================================================================================



ITEM 2.02.  RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

         On August 25, 2006, Immunomedics, Inc., a Delaware corporation (the
"Company"), issued a press release to report the Company's financial results for
the fiscal year ended and quarter ended June 30, 2006. The full text of the
press release is attached to this current report on Form 8-K as Exhibit 99.1.*

ITEM 9.01.  FINANCIAL STATEMENTS AND EXHIBITS.

       (d)  Exhibits.

       Exhibit No.  Description
       -----------  ------------------------------------------------------------
          99.1       Press Release of Immunomedics, Inc. dated August 25, 2006
                    reporting its financial results.

         * The information in this Form 8-K shall not be deemed "filed" for
purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange
Act") or otherwise subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the Securities Act of 1933
or the Exchange Act, except as expressly set forth by specific reference in such
a filing.



                                   SIGNATURES
                                   ----------

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                                  IMMUNOMEDICS, INC.


                                                  By:    /s/ Cynthia L. Sullivan
                                                         -----------------------
                                                  Name:  Cynthia L. Sullivan
                                                  Title: President and
                                                         Chief Executive Officer

Date:  August 25, 2006